Joseph J Dobbins, Samuel J Tingle, Jennifer Mehew, Emily R Thompson, Georgios Kourounis, Stuart McPherson, Steve A White, Colin H Wilson
{"title":"供体转氨酶对肝移植利用率和不必要的器官丢弃的影响:全国登记队列研究。","authors":"Joseph J Dobbins, Samuel J Tingle, Jennifer Mehew, Emily R Thompson, Georgios Kourounis, Stuart McPherson, Steve A White, Colin H Wilson","doi":"10.3389/frtra.2024.1458996","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Donor liver transaminases (ALT and AST) have been used to decline livers for transplant, despite evidence that they do not influence transplant outcomes. This study assesses the effect that raised donor transaminases have on the unnecessary decline of livers.</p><p><strong>Methods: </strong>This retrospective cohort study used the National Health Service registry on adult liver transplantation (2016-2019). Logistic regression models were built to assess the impact of donor transaminases on the utilisation of organs donated following brain stem death (DBD) and circulatory death (DCD). A further model was used to simulate the impact on liver decline if raised donor ALT was not used to make utilisation decisions.</p><p><strong>Results: </strong>5,424 adult livers were offered for transplant, of which 3,605 were utilised (2,841 DBD, 764 DCD). In multivariable analysis, adjusted for key factors, increasing peak donor ALT independently increased the odds of liver decline (DBD aOR = 1.396, 1.305-1.494, <i>p</i> < 0.001, DCD aOR = 1.162, 1.084-1.246, <i>p</i> < 0.001). AST was also a significant predictor of liver decline. 18.5% of livers from DBD donors with ALT > 40 U/L (<i>n</i> = 1,683) were declined for transplantation. In this group, our model predicted a 48% (38%-58%) decrease in decline if raised donor ALT was excluded from these decisions. This represents an additional 37 (30-45) liver transplants every year in the UK.</p><p><strong>Conclusions: </strong>Raised donor ALT increased the likelihood of liver decline. As it does not influence transplant outcome, avoiding donor ALT-based organ decline is an immediate and effective way to expand the donor pool.</p>","PeriodicalId":519976,"journal":{"name":"Frontiers in transplantation","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421386/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of donor transaminases on liver transplant utilisation and unnecessary organ discard: national registry cohort study.\",\"authors\":\"Joseph J Dobbins, Samuel J Tingle, Jennifer Mehew, Emily R Thompson, Georgios Kourounis, Stuart McPherson, Steve A White, Colin H Wilson\",\"doi\":\"10.3389/frtra.2024.1458996\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Donor liver transaminases (ALT and AST) have been used to decline livers for transplant, despite evidence that they do not influence transplant outcomes. This study assesses the effect that raised donor transaminases have on the unnecessary decline of livers.</p><p><strong>Methods: </strong>This retrospective cohort study used the National Health Service registry on adult liver transplantation (2016-2019). Logistic regression models were built to assess the impact of donor transaminases on the utilisation of organs donated following brain stem death (DBD) and circulatory death (DCD). A further model was used to simulate the impact on liver decline if raised donor ALT was not used to make utilisation decisions.</p><p><strong>Results: </strong>5,424 adult livers were offered for transplant, of which 3,605 were utilised (2,841 DBD, 764 DCD). In multivariable analysis, adjusted for key factors, increasing peak donor ALT independently increased the odds of liver decline (DBD aOR = 1.396, 1.305-1.494, <i>p</i> < 0.001, DCD aOR = 1.162, 1.084-1.246, <i>p</i> < 0.001). AST was also a significant predictor of liver decline. 18.5% of livers from DBD donors with ALT > 40 U/L (<i>n</i> = 1,683) were declined for transplantation. In this group, our model predicted a 48% (38%-58%) decrease in decline if raised donor ALT was excluded from these decisions. This represents an additional 37 (30-45) liver transplants every year in the UK.</p><p><strong>Conclusions: </strong>Raised donor ALT increased the likelihood of liver decline. As it does not influence transplant outcome, avoiding donor ALT-based organ decline is an immediate and effective way to expand the donor pool.</p>\",\"PeriodicalId\":519976,\"journal\":{\"name\":\"Frontiers in transplantation\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421386/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in transplantation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/frtra.2024.1458996\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/frtra.2024.1458996","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:供体肝脏转氨酶(谷丙转氨酶和谷草转氨酶)一直被用于拒绝移植肝脏,尽管有证据表明它们不会影响移植结果。本研究评估了捐献者转氨酶升高对不必要的肝脏衰竭的影响:这项回顾性队列研究使用了国家卫生服务局的成人肝移植登记表(2016-2019 年)。建立了逻辑回归模型,以评估供体转氨酶对脑干死亡(DBD)和循环死亡(DCD)后捐献器官利用率的影响。另一个模型用于模拟如果不使用捐赠者升高的谷丙转氨酶来做出利用决定,对肝脏衰退的影响:共提供了 5424 个成人肝脏用于移植,其中 3605 个得到利用(2841 个 DBD,764 个 DCD)。在对主要因素进行调整后的多变量分析中,供体ALT峰值的增加会独立增加肝脏衰竭的几率(DBD aOR = 1.396, 1.305-1.494, p p 40 U/L(n = 1,683))。在这组患者中,如果将供体 ALT 升高排除在这些决定之外,我们的模型预测肝功能下降率将下降 48% (38%-58%)。这意味着英国每年将增加37例(30-45例)肝移植:供体ALT升高会增加肝功能衰退的可能性。由于ALT不会影响移植结果,因此避免供体ALT升高导致器官衰竭是扩大供体库的一个直接有效的方法。
Impact of donor transaminases on liver transplant utilisation and unnecessary organ discard: national registry cohort study.
Background: Donor liver transaminases (ALT and AST) have been used to decline livers for transplant, despite evidence that they do not influence transplant outcomes. This study assesses the effect that raised donor transaminases have on the unnecessary decline of livers.
Methods: This retrospective cohort study used the National Health Service registry on adult liver transplantation (2016-2019). Logistic regression models were built to assess the impact of donor transaminases on the utilisation of organs donated following brain stem death (DBD) and circulatory death (DCD). A further model was used to simulate the impact on liver decline if raised donor ALT was not used to make utilisation decisions.
Results: 5,424 adult livers were offered for transplant, of which 3,605 were utilised (2,841 DBD, 764 DCD). In multivariable analysis, adjusted for key factors, increasing peak donor ALT independently increased the odds of liver decline (DBD aOR = 1.396, 1.305-1.494, p < 0.001, DCD aOR = 1.162, 1.084-1.246, p < 0.001). AST was also a significant predictor of liver decline. 18.5% of livers from DBD donors with ALT > 40 U/L (n = 1,683) were declined for transplantation. In this group, our model predicted a 48% (38%-58%) decrease in decline if raised donor ALT was excluded from these decisions. This represents an additional 37 (30-45) liver transplants every year in the UK.
Conclusions: Raised donor ALT increased the likelihood of liver decline. As it does not influence transplant outcome, avoiding donor ALT-based organ decline is an immediate and effective way to expand the donor pool.